Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- 3SBio's Q3 Hurt by Lehman Bankruptcy
- ChinaBio Today submits: 3SBio Inc. SSRX announced a $2.7 million writedown as a consequence of the U.S. financial crisis. The company invested in $3 million of Floating Rate Notes due January 21, 2009 that are subject to the credit of Lehman Brothers. As a consequence of the Lehman Brothers...
- External links 2008-11-04
- China Medical Wrestles with Daunting $345 Million Acquisition
- ChinaBio Today submits: China Medical Technologies CMED told investors it would release a preliminary Q2 (ended September 30, 2008) financial report on November 18, but a full announcement, complete with answering questions from analysts, will wait another month until December 18. As reason for the delay, the company said...
- External links 2008-10-27
- American Oriental Announces Two Acquisitions
- ChinaBio Today submits: American Oriental Bioengineering, Inc. AOB completed two acquisitions while, at the same time, announcing it had declined to pursue a third. In August, AOB had announced a signed letter of intent to pay $110 million to acquire an unnamed China pharmaceutical distributor with $550 million in...
- External links 2008-10-23
- Roche Intent on Discovering Innovative Medicines in China
- ChinaBio Today submits: Roche (RHHBY.PK) has broken ground on an expansion of its facilities at its site in Shanghai’s Zhangjiang Hi-Tech Park, an ambitious expansion that seeks to provide the backbone for the next ten years of the company’s China growth. In addition, Roche has established an office for...
- External links 2008-11-04
- BMP Sunstone's Q3: Revenues on the Rise
- ChinaBio Today submits: BMP Sunstone Corporation BJGP, a company that has been building itself through acquisitions over the last two years, announced very strong Q3 results. It was the first quarter in which results included participation from BMP Sunstone’s acquisition of drug distributor Rongheng. Sunstone announced it acquired a...
- External links 2008-11-12
- Mindray's Q3 Leaves Investors Less Than Pleased
- ChinaBio Today submits: On the face of it, the Q3 financial report issued by Mindray Medical International MR was very positive. Revenues were up 94% at $146.5 million and non-GAAP net income climbed a smaller but still respectable 48% to $33.7 million. Nevertheless, Mindray’s stock price suffered in the...
- External links 2008-11-11
- Charles River Blames Slowdown on Biopharmas' Need to Conserve Cash
- ChinaBio Today submits: Charles River Labs CRL reduced its 2008 profit guidance by 3% because its CRO clients are delaying scheduled tests until next year. The trend caused a small slowing of the company’s growth rate in Q3, but the effect in Q4 will be more pronounced, according to...
- External links 2008-11-08
- TomoTherapy Reduces Dependency on Single Linear Accelerator Manufacturer
- ChinaBio Today submits: TomoTherapy TOMO of Madison, Wisconsin, which makes the Hi•Art treatment system for advanced radiation therapy, will buy privately held Chengdu Twin Peak Accelerator Technology Inc., located in the provincial capital of Sichuan, China. Twin Peak produces linear accelerators, which are used in radiation therapy systems to...
- External links 2008-11-07
- China Sky One Starts Production at New Subsidiary
- ChinaBio Today submits: China Sky One Medical CSKI announced that production has started at the Peng Lai Jin Chuang company facility. China Sky One finalized the acquisition of Jin Chuang last month, paying $7.1 million in cash and stock to gain control of the company. Jin Chuang...
- External links 2008-10-15
Additional Resources
- NeoStem Receives Asia Investment
- ChinaBio Today submits: NeoStem, Inc. NBS completed a $1.25 million private placement from RimAsia Capital Partners, a pan-Asia private equity firm. This appears to be RimAsia’s first investment in a Western company. Previously, RimAsia's invested in China-based enterprises involved in pharmaceutical manufacturing, drug delivery systems, coal blending, print media...
- External links 2008-09-03
- Baxter Plans Big Investment in China Medical Instruments Industry
- ChinaBio Today submits: Baxter International Inc. (NYSE: BAX) recently unveiled a plan to spend 1 billion RMB ($147 million) over the next three years to upgrade factories in Guangzhou, Suzhou, Tianjin and Shanghai. The company positioned the investment as a response to China’s demand for high-quality medical instruments.Baxter said...
- External links 2009-05-23
- China Biopharma Week in Review: Broad Views, Individual Companies
- ChinaBio Today submits: In ChinaBio Today over the past five days, we featured three broad overviews of the China biomedical world, each sourced from an outside publication. The news these articles imparted may seem familiar to our regular readers, who are very aware of the transformation taking place in...
- External links 2008-09-14
- Novartis Seeks to Make China One of Its Top Three Global Markets
- ChinaBio Today submits: Novartis (NYSE: NVS) of Switzerland will begin a five-year, $1 billion China initiative with two aims: the company will dramatically increase its investment in its China R&D facility, and it will seek to make China one its top three markets worldwide. The comments were made by...
- External links 2009-11-04
- GSK Seeks to Increase Emerging Markets Presence with New Vaccine JV
- ChinaBio Today submits: GlaxoSmithKline (NYSE: GSK) has formed a vaccine JV with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (NIBT), an established China vaccine company. The JV will produce flu vaccines for the China market. It will seek to increase GSK’s presence in emerging markets, which is one of the...
- External links 2009-06-10
- NeoStem Raises an Additional $4 Million
- ChinaBio Today submits: NeoStem, Inc. NBS has raised another $4 million from institutional and private investors. The terms of the funding were the same as those for the company’s previous fund raising, an $11 million private placement in April involving three Asia-based investors. Also, affiliates of Suzhou...
- External links 2009-07-05
- Pfizer Is Best Positioned Big Pharma in China - Goldman
- ChinaBio Today submits: In an investment review of Pfizer (NYSE: PFE), Goldman Sachs said sales in emerging growth markets would become a significant factor in the company’s revenues, a fact that it considers underappreciated by stock market investors. China is the major emerging market for Pfizer. Goldman expects...
- External links 2009-11-20
- Shengtai's Future in China Glucose Market Looks Sweet
- ChinaBio Today submits: Shengtai Pharmaceutical, Inc. (SGTI.OB) reported that its revenues climbed 76% in fiscal 2008 (ended June 30) to $91 million. Net Income was up 46% to $10.4 million. Shengtai makes and distributes pharmaceutical grade glucose products in China, as well as glucose and other products for the...
- External links 2008-10-02
- NeoStem Raises $11 Million to Increase China Operations
- ChinaBio Today submits: NeoStem, Inc. (AMEX: NBS) raised $11 million from a private placement with Asian investors. Much of the money will be spent to increase the company’s China operations. In November 2008, NeoStem gained control over a China regenerative medical therapy company, Shandong New Medicine Research Institute of...
- External links 2009-04-14
- China Biotech Gets Off to a Slow Start for 2009
- ChinaBio Today submits: The aftereffects of the holiday season made themselves felt this past week in a greatly constricted news flow from the China biopharma. Although the stories were smaller in number, some of them were, nevertheless, truly significant. Chief among these was the announcement that Singapore biotech S*BIO...
- External links 2009-01-11
- << Previous
- page 1 of 1
- Next >>
Presented by American Express